Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross-over study in patients with critical limb ischemia.

[1]  A. Creutzig,et al.  Intravenous infusion of iloprost in arterial occlusive disease: dose-dependent effects on skin microcirculation , 2004, European Journal of Clinical Pharmacology.

[2]  H. Wilkens,et al.  Cardiac and microcirculatory effects of different doses of prostaglandin E1 in man , 2004, European Journal of Clinical Pharmacology.

[3]  C. Haon,et al.  Prognostic Aspects of TcPO2 in Iloprost Treatment as an Alternative to Amputation , 1999, Angiology.

[4]  T. Wuppermann,et al.  Effect of different compression therapies on the reflux in deep veins with a post-thrombotic syndrome. , 1999, VASA. Zeitschrift fur Gefasskrankheiten.

[5]  H. Sinzinger,et al.  Einfluss von Prostaglandin E1 auf die Endothel-Thrombozyten-Interaktion , 1999 .

[6]  B. Vollert,et al.  PGE-1 und Iloprost Wirkung auf die nutritive Hautdurchblutung und klinische Wirksamkeit bei peripherer arterieller Verschlußkrankheit im Stadium III und IV , 1999 .

[7]  A. Horsch,et al.  Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group. , 1998, VASA. Zeitschrift fur Gefasskrankheiten.

[8]  M. Albring,et al.  Treatment of patients with peripheral arterial occlusive disease Fontaine stage III and IV with intravenous iloprost: an open study in 900 patients. , 1996, Prostaglandins, leukotrienes, and essential fatty acids.

[9]  C. Breuer,et al.  [Prostacyclin (iloprost) as an adjuvant in local surgical therapy of stage IV arterial occlusive disease--is quantification of the therapeutic effect possible with tcPO2 measurements?]. , 1995, VASA. Zeitschrift fur Gefasskrankheiten.

[10]  P. Scheffler,et al.  Cardiopulmonary effects and safety of prostaglandin E1: A review , 1994 .

[11]  W. Kübler,et al.  Prostaglandin E1 in critical limb ischemia transcutaneous PO2: A predictor of efficacy? , 1994 .

[12]  W. Brockhaus,et al.  Treatment of patients with peripheral arterial occlusive disease Fontaine stage IV with intravenous iloprost and PGE1: a randomized open controlled study. , 1993, Prostaglandins, leukotrienes, and essential fatty acids.

[13]  E. Diot,et al.  Treatment of Lower Limb Ischaemia Due to Atherosclerosis in Diabetic and Nondiabetic Patients with Iloprost, a Stable Analogue of Prostacyclin , 1991 .

[14]  G. Leipnitz,et al.  Effects of Intravenous PGE1 on Blood Flow and Microcirculation: A Double-Blind, Placebo-Controlled Study in Patients with Critical Limb Ischaemia , 1991 .

[15]  A. Creutzig,et al.  Transcutaneous Oxygen Pressure at Different Dosages of Intravenous Prostaglandin E1 in Patients with Severe Arterial Occlusive Disease: A Double-Blind, Placebo-Controlled Study , 1991 .

[16]  P. Scheffler,et al.  [Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative]. , 1990, Schweizerische medizinische Wochenschrift.

[17]  L. Norgren,et al.  A stable prostacyclin analogue (iloprost) in the treatment of ischaemic ulcers of the lower limb. A Scandinavian-Polish placebo controlled, randomised multicenter study. , 1990, European journal of vascular surgery.

[18]  C. Diehm,et al.  [Iloprost, a stable prostacyclin derivative, in stage 4 arterial occlusive disease. A placebo-controlled multicenter study]. , 2008, Deutsche medizinische Wochenschrift.

[19]  G. Leipnitz,et al.  Therapeutic efficacy of intravenously applied prostaglandin E1. , 1989, VASA. Supplementum.

[20]  K. Breddin,et al.  Intravenous prostaglandin E1 versus pentoxifylline therapy in chronic arterial occlusive disease--a controlled randomised multicenter study. , 1989, VASA. Supplementum.

[21]  A. Ehrly,et al.  Einfluß einer intravenösen Gabe von Prostaglandin E1 auf den Muskelgewebesauerstoffdruck, die transkutanen Gasdruckwerte und die Fließeigenschaften des Blutes von Patienten im Stadium III und IV der chronischen arteriellen Verschlußkrankheit , 1988 .

[22]  D. Kiessling,et al.  [Transcutaneous pO2 and laser Doppler flux in increasing doses of intraarterial and intravenously administered prostaglandin E1]. , 1987, VASA. Zeitschrift fur Gefasskrankheiten.

[23]  H. Heidrich,et al.  Vitalkapillarmikroskopische Untersuchungen und transkutane p O 2 -Messungen bei intravenöser Prostaglandin-E 1 -Infusion: Akutstudie , 2008 .